Welcome to our dedicated page for REGENTIS BIOMATERIALS LTD. SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
Regentis Biomaterials director Jeff Dykan reported equity compensation consisting of 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each for ordinary shares. The options vest quarterly over three years until fully vested on May 28, 2029, while the warrants are currently exercisable for a three-year term through February 23, 2029. Both awards were approved by the board and became effective after shareholder approval on July 9, 2026.
REGENTIS BIOMATERIALS LTD. reports that its Chief Executive Officer, Ehud Geller, received a grant of 31,250 warrants to purchase an equal number of ordinary shares at an exercise price of $0.0030 per share. These currently exercisable warrants were approved by the board on February 23, 2026, received shareholder approval on July 9, 2026, and have a three-year term expiring on February 23, 2029. Following this award, Geller holds 31,250 warrants of this series directly.
Regentis Biomaterials Ltd. granted director Efraim Cohen-Arazi an employee stock option over 24,826 underlying ordinary shares at an exercise price of 2.1600 per share. The award vests in quarterly 1/12 installments from August 28, 2026 through May 28, 2029, subject to continued employment, and relates to the 2024 Share Option Plan, which may qualify for certain Israeli Section 102 tax benefits via trustee registration.
Regentis Biomaterials Ltd. reports that its Adjourned Annual General Meeting of Shareholders held on July 9, 2026 approved all fourteen proposals presented to shareholders. The proposals, which were outlined in the company’s May 28, 2026 Notice and Proxy Statement and a June 4, 2026 amended notice, each received the required majority support.
Regentis Biomaterials Ltd. is registering for resale up to 3,807,143 Ordinary Shares by selling shareholders, including shares issued in a June 17, 2026 private placement and shares issuable upon exercise of related warrants.
The prospectus states 7,023,921 Ordinary Shares outstanding as of July 8, 2026. The company will not receive proceeds from resale by the selling shareholders, although it may receive approximately $8.21 million if the offered warrants are exercised for cash in full.
Regentis Biomaterials Ltd. convened its Annual General Meeting of Shareholders on July 2, 2026, but the meeting was adjourned for one week due to lack of quorum. The meeting will be reconvened on July 9, 2026 at 3:00 p.m., Israel time, at the offices of the Company’s attorneys in Tel Aviv.
Regentis Biomaterials Ltd. entered into definitive agreements for a private placement expected to raise approximately $6.5 million in gross proceeds. The company will issue 1,844,543 ordinary shares and pre-funded warrants for up to 12,600 shares, together with ordinary warrants for up to 1,857,143 shares at a combined purchase price of $3.50 per ordinary share and warrant, and $3.4999 per pre-funded warrant and warrant.
Pre-funded warrants are immediately exercisable at $0.0001 per share with no expiry until fully exercised, while ordinary warrants are immediately exercisable at $4.20 per share and expire five years after issuance. Placement agent ThinkEquity will receive cash fees totaling 8% of gross proceeds plus up to $180,000 in expense reimbursement and warrants to purchase 92,857 shares at $4.375 per share. Net proceeds are earmarked to fund the pivotal GelrinC trial, U.S. FDA pre-market approval preparation, Gelrin platform development, operational readiness, European market entry, and general corporate purposes.
Regentis Biomaterials Ltd., a foreign private issuer based in Israel, reports that it has requested withdrawal of its Registration Statement No. 333-295510 on Form F-1, effective June 15, 2026. The company has decided not to pursue the public offering that was planned under this registration.
Regentis Biomaterials Ltd. filed Amendment No. 1 to its Form F-1 (Registration No. 333-295510) to file an updated Exhibit 23.1 and to amend and restate the Exhibit Index in Part II. The amendment expressly omits prospectus changes in Part I and does not change the offering terms disclosed earlier.
The filing also discloses prior unregistered financings and convertible loans, including aggregate convertible financings of $900,000 (2020 CLAs) and $835,000 (2021 CLAs), conversions into Ordinary Shares, multiple bridge loans and CEO loan arrangements with interest at 8% and related warrants. Signature pages and U.S. authorized representative attestations are included.